Podcast Index
Parcourez les podcasts par catégorie, ouvrez les épisodes récents et téléchargez l’audio pour l’écouter hors ligne.
Pharmaceutical Executive
Pharmaceutical Executive Podcast
Artificial Intelligence Masterclass
AI Masterclass
Quazi Johir
Quazi Johir
A Tale of Two Hygienists Podcast
Jessica Atkinson, RDH and David Torres CRDH
Lorekeeper's Librarium
Tobias Weaver
Sasquatch Experience
Anomalis Entertainment, LLC
Rain & Shine
Calla Rose Ostrander & Kori Stanton
Cuentos y Leyendas de Honduras
Cuentos y Leyendas de Honduras
Oxford Policy Pod
Students at the Blavatnik School of Government, Oxford University
The Poison Lab
Clinical Toxicology LLC
Mises Media
Mises Institute
The Grave Talks | Haunted, Paranormal & Supernatural
Ghost Stores, Haunted, Paranormal & Supernatural Stories
Real Ghost Stories Online
Real Ghost Stories Online | Paranormal, Supernatural & Horror Radio
Mammalwatching
Jon Hall & Charles Foley
Creepypasta zum Einschlafen
Dr. Zargota
Strange and Unexplained
Cristina Gomez
Imaginary Worlds
Eric Molinsky | Daylight Media
Filosofía, Psicología, Historias
Hernán Melana
That Neuroscience Guy
Olav Krigolson
Cosmic Radio
Elizabeth Garcia
Chesapeake Bay Journal Newscast
Chesapeake Bay Journal
Eye On The Sky
Vermont Public
Unleashing Intuition Secrets
Michael Jaco
The Charlie & Duke Show
Eat Sleep Elite
Τα podcasts του Newshub.gr
newshub.gr
Tommy Cullum's Let's Get Freaky
Tommy Cullum
Dark Mysteries — Unsolved Mysteries. Forgotten Secrets. Unanswered Questions.
Darkest Mysteries Online
The Good Dog Pod
Good Dog
DarkHorse Podcast
Bret Weinstein & Heather Heying
Conservation Starters
Thurston Conservation District
Thrilling Threads - Conspiracy Theories, Strange Phenomena, True Crime, Unsolved Mysteries, etc!
Byte & Pieces
Bedrock: Earth's Earliest History
Dylan Wilmeth
Ta de Clinicagem
TdC
Fox Weather Update
Fox Weather
Gut Feelings - by The Crohn's & Colitis Dietitians
The Crohn's & Colitis Dietitians
Under Kappa
Vidar Skogvoll og Even Garvang
JUNKMILES
Björn Geesmann
Science
Pharmaceutical Executive Podcast
In today's Pharmaceutical Executive Daily, AlzeCure Pharma announces a collaboration with QuantumCell ApS worth more than $2.2 billion for global rights to its Neurostore platform including Alzheimer's candidate ACD856, ...
In today's Pharmaceutical Executive Daily, FDA selects seven companies for its new PreCheck Pilot Program, Kirsten Whipple examines how the concept of healthspan is emerging from academic obscurity into a powerful consum...
In today's Pharmaceutical Executive Daily, a pharma M&A roundup covers Ipsen's up to $1.75 billion acquisition of Kartos Therapeutics and Zymeworks' $929 million acquisition of Theravance Biopharma, Krista Pinto of Evers...
In today's Pharmaceutical Executive Daily, Eli Lilly and Abbisko Therapeutics announce a new strategic research collaboration in which Abbisko will leverage its early-stage drug discovery platform to advance targets sele...
In today's Pharmaceutical Executive Daily, the FDA announces Operation TrialBlazer, a pilot program aimed at cutting early-stage clinical trial timelines by six to 12 months as the US looks to reclaim its footing in glob...
In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding a suite of clinical-stage immunology assets to its portfolio, Insilico Medicine enters an AI-po...
In today's Pharmaceutical Executive Daily, an FDA advisory committee votes unanimously in favor of the benefit-risk profile of Moderna's investigational mRNA-1010 seasonal influenza vaccine across both younger and older ...
In today's Pharmaceutical Executive Daily, Biogen announces its second acquisition of 2026, a deal worth up to $1 billion for private immunology biotech RayThera, FDA approves Utebzi as the first and only oral carbapenem...
In today's Pharmaceutical Executive Daily, FDA staff release briefing documents flagging evidence gaps in Moderna's mRNA flu vaccine, a pharma roundup covers Merck's $510 million collaboration with Protillion Biosciences...
In today's Pharmaceutical Executive Daily, Elicio Therapeutics shares tumble after its Phase II Amplifgy-7P trial of KRAS-targeting immunotherapy ELI-002 7P misses its primary endpoint in adjuvant pancreatic cancer, FDA ...
In today's Pharmaceutical Executive Daily, Boehringer Ingelheim's Brian Hilberdink argues that obesity innovation must evolve beyond the scale, a pharma regulatory roundup covers two significant FDA approvals, and Pharma...
In today's Pharmaceutical Executive Daily, Kardigan sets terms for a $350 million IPO that would value the cardiovascular biotech at approximately $1.3 billion, Pharmaceutical Executive speaks with Rick Winningham on bui...
In today's Pharmaceutical Executive Daily, Bruce Liu examines China's latest policy guidance establishing premium pricing and priority reimbursement access for truly innovative drugs, Parabilis Medicines surges more than...
In today's Pharmaceutical Executive Daily, Parabilis Medicines prices a record-breaking $670 million IPO, Swedish biotech AlzeCure Pharma enters a collaboration and out-licensing agreement with Eli Lilly for its Alzheime...
In this episode, Ron Lanton draws on insights from the JP Morgan Healthcare Conference to explain how healthcare investment is shifting from backing novel ideas to funding organizations that can scale, survive regulatory...
In today's Pharmaceutical Executive Daily, a pharma funding roundup covers two RNA-focused biotechs that secured fresh capital, GSK announces a $10.6 billion agreement to acquire Nuvalent in its largest deal in over a de...
In today's Pharmaceutical Executive Daily, Roche and Nurix Therapeutics announce a global collaboration, a pharma M&A roundup covers three deals announced today, and Pharmaceutical Executive contributors examine how an e...
In today's Pharmaceutical Executive Daily, the Supreme Court unanimously rules in favor of Hikma Pharmaceuticals in its patent dispute with Amarin over Vascepa, Pfizer licenses Chai Discovery's generative AI platform, an...
In today's Pharmaceutical Executive Daily, Eli Lilly escalates its 340B enforcement standoff by notifying covered entities of a five-business-day window to submit required claims data or lose access to 340B pricing, Alny...
Remplissez le formulaire ci-dessous. Veillez à sélectionner à la fois Pays et Genres.
Envoyez-nous un message ci-dessous. Nous vous répondrons dans les 24 heures.